Oral News and Research

RSS

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

U.S. Supreme Court to hear oral arguments to decide fate of anti-prostitution pledge

"On Monday, the Supreme Court hears oral arguments in a case that will decide if recipients of government aid can be forced to oppose prostitution -- or potentially any other issue as a contingency of receiving U.S. funds," The Nation reports.

23 Apr 2013

Oncology nurses explore how to better combat patient fatigue

They are key members of the healthcare team who face ongoing challenges on how best to provide optimum care to patients affected by cancer. Oncology nurses at The Cancer Institute of New Jersey continually strive to improve patient care and have recently explored how to better combat patient fatigue, the importance of documenting sleep-wake disturbances and the development of a toolkit to help patients better follow their oral treatment schedule during clinical trials.

23 Apr 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.

23 Apr 2013

Women & Infants Hospital physician to study treatment options for heavy menstrual bleeding

Kristen A. Matteson, MD, MPH, of the Department of Obstetrics and Gynecology at Women & Infants Hospital and assistant professor of obstetrics and gynecology at The Warren Alpert Medical School of Brown University, has earned a $1.6 million grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health to study the effectiveness of two treatments options for heavy menstrual bleeding.

23 Apr 2013

$Study shows 30.4% of hip fracture patients in India died within one year$

Study shows 30.4% of hip fracture patients in India died within one year

In various studies across different countries the reported one year mortality risks after hip fracture can vary anywhere from 5 to 50 %. In India, however, there has been little research on the risk of mortality and functional impairment following hip fracture.

23 Apr 2013

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Aeterna Zentaris Inc. today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide® product.

22 Apr 2013

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

22 Apr 2013

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and dysphagia/odynophagia. In clinical practice, dysphagia is most often defined as difficulty in swallowing and odynophagia is defined as pain upon swallowing.

22 Apr 2013

National Foundation for Infectious Diseases to host 16th Annual Conference on Vaccine Research

The National Foundation for Infectious Diseases will host the 16th Annual Conference on Vaccine Research, April 22-24, 2013, at the Hyatt Regency Inner Harbor in Baltimore, MD.

22 Apr 2013

$Young athletes undergoing intense training have higher risk of stress fractures, other overuse injuries$

Young athletes undergoing intense training have higher risk of stress fractures, other overuse injuries

Young athletes who specialize in one sport and train intensively have a significantly higher risk of stress fractures and other severe overuse injuries, even when compared with other injured athletes, according to the largest clinical study of its kind.

22 Apr 2013

IMRT reduces feelings of dry mouth in patients with head and neck cancers

Geneva, Switzerland: Researchers have shown for the first time that it is possible to reduce the distressing symptoms of dry mouth in patients treated with radiotherapy for head and neck cancers if the radiation dose to a salivary gland (called the submandibular gland) on the opposite side to the tumour is kept to the minimum.

22 Apr 2013

Edible malarial vaccine may work against other viral and bacterial infections

Can scientists rid malaria from the Third World by simply feeding algae genetically engineered with a vaccine? That's the question biologists at UC San Diego sought to answer after they demonstrated last May that algae can be engineered to produce a vaccine that blocks malaria transmission.

22 Apr 2013

Sleep related breathing disorders associated with cognitive and behavioral impairment in children

People lobbying for gun control may want to consider another culprit in the post-Newtown search for the answer to our unfathomable questions.

22 Apr 2013

Potential therapies for smell loss

Snot. It's not something most of us spend a lot of time thinking about, but, for a team of researchers in Washington, D.C., it's front and center.

22 Apr 2013

Oral News and Research

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

U.S. Supreme Court to hear oral arguments to decide fate of anti-prostitution pledge

Oncology nurses explore how to better combat patient fatigue

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Women & Infants Hospital physician to study treatment options for heavy menstrual bleeding

Study shows 30.4% of hip fracture patients in India died within one year

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

National Foundation for Infectious Diseases to host 16th Annual Conference on Vaccine Research

Young athletes undergoing intense training have higher risk of stress fractures, other overuse injuries

IMRT reduces feelings of dry mouth in patients with head and neck cancers

Edible malarial vaccine may work against other viral and bacterial infections

Sleep related breathing disorders associated with cognitive and behavioral impairment in children

Potential therapies for smell loss

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News